This means semaglutide requires much smaller syringe volumes at comparable concentrations
Zhang et al., 2010
Vacca, A., Ribatti, D., Iurlaro, M., Merchionne, F., Nico, B., Ria, R., et al
No human clinical trials exist yet, and regulatory access has been limited since 2023
In terms of selecting the formulation delivery device, in a human study with a whole-virus influenza liquid vaccine without adjuvant, the immune response was better when using the breath-powered Bi-Directional OptiNose device and nasal drops in the delivery, rather than traditional nasal spray and an oral spray [22]
If additional peptides are studied alongside GLOW, run GLOW at its documented schedule first and introduce anything else only after establishing a stable baseline